<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362149">
  <stage>Registered</stage>
  <submitdate>23/02/2012</submitdate>
  <approvaldate>23/02/2012</approvaldate>
  <actrnumber>ACTRN12612000234819</actrnumber>
  <trial_identification>
    <studytitle>Effect of steroids on blood sugar levels and risk of heart disease in pituitary patients</studytitle>
    <scientifictitle>Effect of glucocorticoid replacement dose on cardiovascular risk and postprandial blood glucose in hypopituitary patients</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Secondary adrenal insufficiency</healthcondition>
    <healthcondition>Hypopituitarism</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>An open interventional study assessing the effect of increasing oral glucocorticoid dose on arterial stiffness, endothelial function and autonomic nervous system activity.

Subjects will be studied on their usual oral glucocorticoid dose and then again after increasing their oral glucocorticoid dose to hydrocortisone equivalent 30 mg/day for 7 days. 

At each study visit, subjects will be studied before and after drinking an oral glucose load (75 g)</interventions>
    <comparator>Nil</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary endpoint is the change in pulse wave velocity with higher glucocorticoid dose, assessed by paired t-tests.</outcome>
      <timepoint>After increased glucocorticoid dose for 7 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in autonomic nervous system activity as reflected in baroreceptor sensitivity (slope), measured using the TaskForce Monitor (CNSystems)</outcome>
      <timepoint>After increased glucocorticoid dose for 7 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in endothelial function as reflected in Reactive Hyperaemia Index as calculated by the EndoPAT (Itamar Medical)</outcome>
      <timepoint>After increased glucocorticoid dose for 7 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The correlation between changes in post-glucose load glucose concentration and insulin sensitivity and markers of cardiovascular risk. 

Post-glucose load glucose concentration will be determined by blood test after an oral glucose load (75g). Insulin sensitivity will be estimated based on the insulin and glucose results during the oral glucose tolerance test. Markers of cardiovascular risk are as listed above (pulse wave velocity, autonomic nervous system function, endothelial function). Statistical correlation analysis will be performed on the results - the test used will depend on whether the results are parametric or non-parametric.</outcome>
      <timepoint>After increased glucocorticoid dose for 7 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Hydrocortisone less than or equal to 20mg per day (or other glucocorticoid at equivalent dose)
GC use for at least 6 months
Age greater than or equal to 20 years</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Atrial fibrillation
Beta blocker medication
Raynauds phenomenon
Inability to provide written informed consent
On treatment for diabetes</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Educational / counselling / training</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>25/02/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Morton Burt</primarysponsorname>
    <primarysponsoraddress>Southern Adelaide Diabetes and Endocrine Services
Repatriation General Hospital
Daws Rd
Daw Park
SA 5041</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Pfizer CVL Grant</fundingname>
      <fundingaddress>Fellowship &amp; Grants Coordinator 
Medical Department 
Pfizer Australia 
38-42 Wharf Road 
West Ryde NSW 2114 
Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Flinders Medical Centre Foundation</fundingname>
      <fundingaddress>Flinders Medical Centre
Flinders Drive
Bedford Park
SA 5042</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Flinders Medical Centre</sponsorname>
      <sponsoraddress>Flinders Drive
Bedford Park
SA 5042</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study aims to assess whether higher doses of steroids increase the risk of heart disease in pituitary patients.

We hope that this study will increase the understanding of the effects of steroid replacement dose in patients with pituitary disorders. This information may influence what doses of steroid replacement are optimal for the long-term health of pituitary patients.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Flinders Clinical Research Ethics Committee</ethicname>
      <ethicaddress>Flinders Medical Centre
Flinders Drive
Bedford Park
SA 5042</ethicaddress>
      <ethicapprovaldate>13/12/2010</ethicapprovaldate>
      <hrec>1/10/0401</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Morton Burt</name>
      <address>Southern Adelaide Diabetes and Endocrine Services
Repatriation General Hospital
Daws Rd
Daw Park
SA 5041</address>
      <phone>+61 8 8275 1094</phone>
      <fax>+61 8 8275 1215</fax>
      <email>morton.burt@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Morton Burt</name>
      <address>Southern Adelaide Diabetes and Endocrine Services
Repatriation General Hospital
Daws Rd
Daw Park
SA 5041</address>
      <phone>+61 8 8275 1094</phone>
      <fax>+61 8 8275 1215</fax>
      <email>morton.burt@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Carolyn Petersons</name>
      <address>Southern Adelaide Diabetes and Endocrine Services
Repatriation General Hospital
Daws Rd
Daw Park
SA 5041</address>
      <phone>+61 8 8275 1094</phone>
      <fax>+61 8 8275 1215</fax>
      <email>carolyn.petersons@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>